Emergence of HBV resistance to lamivudine (3TC) in HIV/HBV co-infected patients in the Gambia, West Africa

BMC Research Notes

Volumn 4, Issue , 2011, Pages

  Stewart, Balint ^a   Jobarteh, Modou L ^a   Sarge Njie, Ramu ^a   Alabi, Abraham ^a,b   De Silva, Thushan ^a   Peterson, Kevin ^a   Peterson, Ingrid ^a   Whittle, Hilton ^a   Rowland Jones, Sarah ^a,c   Jaye, Assan ^a   Cotten, Matthew ^a,d   Mendy, Maimuna ^a,e  

^a MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^b ALBERT SCHWEITZER HOSPITAL   (Gabon)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^e INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2;

EID: 84155191001     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-4-561     Document Type: Article

References (27)

1. Management of chronic hepatitis B and C in HIV-coinfected patients. Soriano V, Barreiro P, Nunez M, J Antimicrob Chemother 2006 57 815 818 10.1093/jac/dkl068 16556638
2. Seroprevalence of hepatitis B and C virus in HIV-1 and HIV-2 infected Gambians. Jobarteh M, Malfroy M, Peterson I, Jeng A, Sarge-Njie R, Alabi A, et al. Virol J 2010 7 230 10.1186/1743-422X-7-230 20843322
3. Hepatitis B virus infection in two Gambian villages. Whittle HC, Bradley AK, McLauchlan K, Ajdukiewicz AB, Howard CR, Zuckerman AJ, et al. Lancet 1983 1 1203 1206 6133999 (Pubitemid 13092718)
4. Antiretroviral therapy for hepatitis B virus-HIV-coinfected patients: promises and pitfalls. Levy V, Grant RM, Clin Infect Dis 2006 43 904 910 10.1086/507532 16941375 (Pubitemid 44435521)
5. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. de Jongh FE, Janssen HL, de Man RA, Hop WC, Schalm SW, van Blankenstein M, Gastroenterology 1992 103 1630 1635 1426884
6. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B, Munoz A, et al. Lancet 2002 360 1921 1926 10.1016/S0140-6736(02) 11913-1 12493258 (Pubitemid 35472132)
7. Biochemical pharmacology of (+)- and (-)-2',3'-dideoxy-3'-thiacytidine as anti-hepatitis B virus agents. Chang CN, Skalski V, Zhou JH, Cheng YC, J Biol Chem 1992 267 22414 22420 1331054
8. Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients. Westland CE, Yang H, Delaney WE, Wulfsohn M, Lama N, Gibbs CS, et al. J Viral Hepat 2005 12 67 73 10.1111/j.1365-2893.2005.00578.x 15655050 (Pubitemid 40188776)
9. YSDD: a novel mutation in HBV DNA polymerase confers clinical resistance to lamivudine. Bozdayi AM, Uzunalimoglu O, Turkyilmaz AR, Aslan N, Sezgin O, Sahin T, et al. J Viral Hepat 2003 10 256 265 10.1046/j.1365-2893.2003.00435.x 12823591 (Pubitemid 36801911)
10. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Melegari M, Scaglioni PP, Wands JR, Hepatology 1998 27 628 633 10.1002/hep.510270243 9462667 (Pubitemid 28081083)
11. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. Ono SK, Kato N, Shiratori Y, Kato J, Goto T, Schinazi RF, et al. J Clin Invest 2001 107 449 455 10.1172/JCI11100 11181644 (Pubitemid 32167991)
12. Occult hepatitis B virus infection in HIV-infected patients: Evaluation of biochemical, virological and molecular parameters. Araujo NM, Branco-Vieira M, Silva AC, Pilotto JH, Grinsztejn B, de Almeida AJ, et al. Hepatol Res 2008 38 1194 1203 18624719
13. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Honkoop P, de Man RA, Niesters HG, Zondervan PE, Schalm SW, Hepatology 2000 32 635 639 10.1053/jhep.2000.16333 10960461
14. Efficacy of hepatitis B vaccine against antiviral drug-resistant hepatitis B virus mutants in the chimpanzee model. Kamili S, Sozzi V, Thompson G, Campbell K, Walker CM, Locarnini S, et al. Hepatology 2009 49 1483 1491 10.1002/hep.22796 19274751
15. Selection of hepatitis B virus (HBV) vaccine escape mutants in HBV-infected and HBV/HIV-coinfected patients failing antiretroviral drugs with anti-HBV activity. Sheldon J, Ramos B, Garcia-Samaniego J, Rios P, Bartholomeusz A, Romero M, et al. J Acquir Immune Defic Syndr 2007 46 279 282 10.1097/QAI.0b013e318154bd89 18167643 (Pubitemid 350287353)
16. Impact of hepatitis B virus infection on human immunodeficiency virus response to antiretroviral therapy in Nigeria. Idoko J, Meloni S, Muazu M, Nimzing L, Badung B, Hawkins C, et al. Clin Infect Dis 2009 49 1268 1273 10.1086/605675 19772386
17. Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion. Chu CM, Liaw YF, J Viral Hepat 2007 14 147 152 10.1111/j.1365-2893.2006.00810.x 17305879
18. Current treatment of HIV/hepatitis B virus coinfection. Iser DM, Sasadeusz JJ, J Gastroenterol Hepatol 2008 23 699 706 10.1111/j.1440-1746.2008. 05382.x 18410604 (Pubitemid 351519434)
19. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. Rockstroh JK, Bhagani S, Benhamou Y, Bruno R, Mauss S, Peters L, et al. HIV Med 2008 9 82 88 10.1111/j.1468-1293.2007.00535.x 18257771 (Pubitemid 351228130)
20. HIV-2: the forgotten AIDS virus. de Silva TI, Cotten M, Rowland-Jones SL, Trends Microbiol 2008 16 588 595 10.1016/j.tim.2008.09.003 18964021
21. Mutations associated with lamivudine-resistance in therapy-naive hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients. Selabe SG, Lukhwareni A, Song E, Leeuw YG, Burnett RJ, Mphahlele MJ, J Med Virol 2007 79 1650 1654 10.1002/jmv.20974 17854040 (Pubitemid 47479881)
22. Long-term hepatitis B virus dynamics in HIV-hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate. Lacombe K, Gozlan J, Boelle PY, Serfaty L, Zoulim F, Valleron AJ, et al. AIDS 2005 19 907 915 10.1097/01.aids.0000171404.07995.5c 15905671 (Pubitemid 40834933)
23. Hepatitis B vaccination in infancy in The Gambia: protection against carriage at 9 years of age. Viviani S, Jack A, Hall AJ, Maine N, Mendy M, Montesano R, et al. Vaccine 1999 17 2946 2950 10.1016/S0264-410X(99)00178-4 10462228 (Pubitemid 29366973)
24. Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the Gambia and emergence of drug-resistant variants. Jallow S, Alabi A, Sarge-Njie R, Peterson K, Whittle H, Corrah T, et al. J Clin Microbiol 2009 47 2200 2208 10.1128/JCM.01654-08 19420165
25. Application of real-time PCR to quantify hepatitis B virus DNA in chronic carriers in The Gambia. Mendy ME, Kaye S, Van der Sande M, Rayco-Solon P, Waight PA, Shipton D, et al. Virol J 2006 3 23 10.1186/1743-422X-3-23 16594999 (Pubitemid 43951842)
26. Prevalence of HBV core promoter/precore/core mutations in Gambian chronic carriers. Dumpis U, Mendy M, Hill A, Thursz M, Hall A, Whittle H, et al. J Med Virol 2001 65 664 670 10.1002/jmv.2088 11745929 (Pubitemid 33135093)
27. Changes in viral load and HBsAg and HBeAg status with age in HBV chronic carriers in The Gambia. Mendy ME, McConkey SJ, Sande van der MA, Crozier S, Kaye S, Jeffries D, et al. Virol J 2008 5 49 10.1186/1743-422X-5-49 18416832 (Pubitemid 351641965)